Standard Biotools (LAB) Net Margin (2010 - 2026)

Standard Biotools (LAB) has reported Net Margin for 17 consecutive years, with 133.15% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin rose 2060.0% year-over-year to 133.15% in Q2 2026; TTM through Jun 2026 was 100.35%, a 23598.0% increase from a year earlier, with the FY2025 full-year figure at 87.77%, up 11540.0% from the prior year.
• Net Margin was 133.15% for Q2 2026 at Standard Biotools, down from 600.91% in the prior quarter.
• Over five years, Net Margin peaked at 600.91% in Q1 2026 and troughed at 338.39% in Q2 2022.
• A 5-year average of 82.64% and a median of 118.35% in 2022 frame the typical range for Net Margin.
• Across the five-year window, Net Margin plunged 28205 bps in 2022 and jumped 72964 bps in 2026, its largest moves.
• Over 5 years, Net Margin stood at 77.14% in 2022, then soared by 83 bps to 13.27% in 2023, then slumped by 936 bps to 137.51% in 2024, then jumped by 159 bps to 81.04% in 2025, then sank by 264 bps to 133.15% in 2026.
• The last three Net Margin figures came in at 133.15% (Q2 2026), 600.91% (Q1 2026), and 81.04% (Q4 2025), per Business Quant data.